There is no passion to be found in playing small - in settling for a life that is less than you are capable of living.” — Nelson Mandela

Our Vision

Progressing African Healthcare

Our Mission

Restoring, Preserving and Advancing the health of all patients

Our Strategy

By Providing World-Class Healthcare Solutions

About Us

Kiara Health (Pty) Ltd is an African pharmaceutical manufacturing and healthcare solutions company headquartered in Johannesburg, South Africa. It serves as the local, non-exclusive manufacturing partner for a Global Top 5 pharmaceutical company and as a commercial partner for several global pharmaceutical and medical technology companies.

In August 2020, Imperial Logistics invested in Kiara Health. Kiara’s aspiration to deliver world-class medical solutions to all patients on the African continent resonates strongly with Imperial’s purpose to connect Africa and the world and to improve people’s lives with access to quality products and services.


Ranked among the Top 30 Global Logistics companies


Countries in which Imperial operates


Million patient lives accessed in SSA

Our Partners

Kiara Health News

Read more about our latest articles, white papers, and other media.

Kiara Health is Proud to Have Won an Award at the Prestigious Ansarada DealMakers Annual Awards 2020

Kiara acquired the internationally GMP compliant Novartis plant, and twenty-six marketing authorisations (MAs) from Novartis’ subsidiary generic drugs manufacturer, Sandoz South Africa, contract manufacturing selected products for Sandoz SA for a four-year period.

Kiara Health – The First and Only Company in Africa with a Fully Scaled Server Deployment in the AWS Cloud

Kiara Health is officially the first and only customer on the African continent with a fully scaled server deployed in the AWS Cloud.

Spread the Word, Not Malaria

Kiara Health (Pty) Ltd is proud to have been chosen as the partner, in select SSA markets, to Shin Poong Pharmaceutical Co. Ltd., South Korea, for the marketing and distribution of their WHO prequalified artesunate-pyronaridine (AS-PY) fixed-dose antimalarial combination, co-developed with Medicines for Malaria Venture (MMV).